Repurposing epetraborole to combat <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> infections.

ABSTRACT: Neisseria gonorrhoeae and Chlamydia trachomatis are the most common bacterial sexually transmitted infections. The World Health Organization (WHO) estimates that there were approximately 211 million cases of chlamydia and gonorrhea in 2020. Currently, no single drug is effective against both pathogens. Ceftriaxone (CRO) is the only recommended treatment for gonococcal infections but has no activity against C. trachomatis. Azithromycin (AZM) or doxycycline (DOX) is recommended for C. trachomatis infections; however, N. gonorrhoeae has developed resistance to both agents. Without new therapeutic options, these infections risk becoming untreatable. Utilizing a drug repurposing approach, we identified epetraborole (EBO) as a potent inhibitor for

SUBMITTER: Abdelsattar AS 

PROVIDER: S-EPMC12777565 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature